Bionano Genomics, Inc. (BNGO)

BNGO insiders just BOUGHT more shares this month May15th, May 16th & May 17th 2022 SEC filings show insiders buying more shares, that is always a good sign for future growth. I bought more shares also
BNGO could go back over $10 again 2022 as sales grow

It appears the dishonest shorts lying again......as usual

What's China got to do with it? announced the publication of an evaluation of OGM from The First Affiliated Hospital of Zhengzhou, the largest hospital in Central China, highlighting the utility of OGM for structural variant analysis, including in a workflow for preimplantation genetic testing.

In this study, researchers, led by Dr. Xiangdong Kong, evaluated the use of OGM to detect chromosome balanced translocations and compared results to a variety of methods, including karyotype analysis, FISH, and CNV-seq. Balanced reciprocal translocations are one of the most common chromosomal abnormalities and may lead to infertility, recurrent pregnancy loss, or genetic defects. Analysis of this abnormality may be helpful in the screening and analysis of embryos prior to implantation, as part of fertility treatment. The paper suggests a need for new methods to complement existing analysis techniques, such as karyotype and FISH, which are described as time consuming and relatively low-resolution, and next generation sequencing (NGS) which can enable copy number variation (CNV) analyses at the whole genome level but cannot be used to detect chromosomal translocations or inversions. The authors demonstrated that OGM performed well in the analysis of these variants, which led them to suggest that OGM could be used as part of the workflow to detect chromosomal abnormalities at a higher resolution.

“We believe this paper highlights the growing validation of OGM in different applications for clinical research in cytogenetics. The work by Dr. Kong and his team at Zhengzhou University further extends this validation and highlights the utility of OGM. Incorporating OGM data in the analysis of embryos prior to implantation is innovative and the approach could be part of a solution for recurrent pregnancy loss, which represents an area of unmet need globally,” Money Sales or Sales Money......

These numbers suggest BNGO needs to grow martlet penetration much, much faster…facts that show vastly improved efficiency of Safire vs legacy systems will be necessary to create this growth, nothing else than a world beating product will be of importance…product will have to sell itself….BNGO margins and growth kind of suck vs ramped up costs and cash burn…still time, but it’s a tighter race the the management and analysts are acknowledging: “ Total revenue for Q1 2022 was $5.7 million, up 80% from Q1 2021.

Gross margin for Q1 2022 was 15%, compared to 33% from Q1 2021. The decrease was primarily due to low yields on our chip consumables produced at one of our contract manufacturers. Gross margin improved over the fourth quarter of 2021 of 4%, primarily due to lower write-off of inventory.

Q1 2022 GAAP operating expense was $30.8 million, compared to $12.2 million in Q1 2021. Q1 2022 non-GAAP1 operating expense was $24.3 million, compared to $11.8 million in Q1 2021. Q1 2022 non-GAAP operating expense excludes $5.1 million in stock-based compensation, and $1.4 million in amortization of intangibles. The year-over-year increase was primarily due to increased headcount-related spending, increased R&D expense, and increased marketing expenses.

At March 31, 2022, the Company had cash, cash equivalents, and available-for-sale securities of $216.5 million.”